Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer

Small ◽  
2015 ◽  
Vol 11 (34) ◽  
pp. 4321-4333 ◽  
Author(s):  
Caina Xu ◽  
Ping Wang ◽  
Jingpeng Zhang ◽  
Huayu Tian ◽  
Kinam Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Ph Sensitive ◽  
Metastatic Lung Cancer ◽  
Metastatic Lung

pH-sensitive tangeretin-ZnO quantum dots exert apoptotic and anti-metastatic effects in metastatic lung cancer cell line

2018 ◽  
Vol 92 ◽  
pp. 477-488 ◽  
Author(s):  
A. Roshini ◽  
Srikanth Jagadeesan ◽  
Lakshmi Arivazhagan ◽  
Young-Jae Cho ◽  
Jong-Hwan Lim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Quantum Dots ◽  
Cell Line ◽  
Cancer Cell ◽  
Cancer Cell Line ◽  
Ph Sensitive ◽  
Lung Cancer Cell Line ◽  
Metastatic Lung Cancer ◽  
Lung Cancer Cell ◽  
Metastatic Lung

A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer

RSC Advances ◽  
2015 ◽  
Vol 5 (125) ◽  
pp. 103380-103385 ◽  
Author(s):  
Caina Xu ◽  
Huayu Tian ◽  
Hai Sun ◽  
Zixue Jiao ◽  
Ying Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Delivery System ◽  
Ph Sensitive ◽  
Metastatic Lung Cancer ◽  
Pulmonary Administration ◽  
Metastatic Lung

Doxorubicin was conjugated to PEI by hydrazone bonds to form a pH sensitive conjugate (PEI-HZ-DOX). The complex particles (PEI-HZ-DOX/Bcl2) could be co-delivered to cancer cells by pulmonary administration. ​

Sleep Disturbances in Metastatic Lung Cancer

2019 ◽  
Author(s):  
M. Kaous ◽  
D.D. Balachandran ◽  
G. Pacheco ◽  
S.A. Mahoney ◽  
J.N.T. Po ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Sleep Disturbances ◽  
Metastatic Lung Cancer ◽  
Metastatic Lung

scholarly journals Patients with Metastatic Lung Cancer and Oncologists’ Views on Achievement of Treatment Goals and Making the Right Treatment Decision: A Prospective Multicenter Study

2021 ◽  
pp. 0272989X2199895
Author(s):  
Adinda Mieras ◽  
Annemarie Becker-Commissaris ◽  
Hanna T. Klop ◽  
H. Roeline W. Pasman ◽  
Denise de Jong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multicenter Study ◽  
Systemic Treatment ◽  
Treatment Decision ◽  
Treatment Goals ◽  
Metastatic Lung Cancer ◽  
Prospective Multicenter Study ◽  
Cancer Data ◽  
Metastatic Lung ◽  
The Right

Background Previous studies have investigated patients’ treatment goals before starting a treatment for metastatic lung cancer. Data on the evaluation of treatment goals are lacking. Aim To determine if patients with metastatic lung cancer and their oncologists perceive the treatment goals they defined at the start of systemic treatment as achieved after treatment and if in hindsight they believe it was the right decision to start systemic therapy. Design and Participants A prospective multicenter study in 6 hospitals across the Netherlands between 2016 and 2018. Following systemic treatment, 146 patients with metastatic lung cancer and 23 oncologists completed a questionnaire on the achievement of their treatment goals and whether they made the right treatment decision. Additional interviews with 15 patients and 5 oncologists were conducted. Results According to patients and oncologists, treatment goals were achieved in 30% and 37% for ‘quality of life,’ 49% and 41% for ‘life prolongation,’ 26% and 44% for ‘decrease in tumor size,’ and 44% for ‘cure’, respectively. Most patients and oncologists, in hindsight, felt they had made the right decision to start treatment and also if they had not achieved their goals (72% and 93%). This was related to the feeling that they had to do ‘something.’ Conclusions Before deciding on treatment, the treatment options, including their benefits and side effects, and the goals patients have should be discussed. It is key that these discussions include not only systemic treatment but also palliative care as effective options for doing ‘something.’

Surgical treatment of cerebral metastases from lung cancer

1971 ◽  
Vol 35 (4) ◽  
pp. 416-420 ◽  
Author(s):  
Edwin E. MacGee
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Operative Mortality ◽  
Cerebral Metastases ◽  
Cerebral Metastasis ◽  
Metastatic Lung Cancer ◽  
Content Type ◽  
Intracranial Surgery ◽  
Metastatic Lung ◽  
Fine Print

✓ Results in 27 cases of intracranial surgery for metastatic lung cancer are evaluated with regard to both the quality and duration of survival; 56% of the patients lived more than 1 year, with the longest survivor still living 32 months after operation. The operative mortality was 26%. These data suggest that intracranial surgery is worthwhile in patients with lung cancer when the cerebral metastasis is either solitary or single.

Sign in / Sign up

Export Citation Format

Share Document